eli lilly glp 1 stock analysis Outlook Has 140% Upside Amid GLP-1 Drug Growth: Goldman Eli Lilly Q1 2025 slides:

Tonneijck, L., Muskiet, M

31 These concerns are supported by preclinical work by Perfetti et al

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings

This approval targets those in early-stage CKD (stages 13) who also face increased cardiovascular risks and struggle with blood sugar control

This was reflected in their EDE-Q scores which reduced by 3.5 and 0.7 points for P2 and P5 respectively

Its eliminated cravings. (P1, male, obesity) I dont snack as much now.Crisps, pringles, that would be a cravingI dont even touch them now. (P8, female, diabetes)